{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "RARE",
  "name": "Ultragenyx Pharmaceutical Inc.",
  "url": "https://orbyd.app/dossiers/RARE/",
  "json_url": "https://orbyd.app/dossiers/RARE.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "The +50% June reset rally round-tripped from ~$33.46 to $28.62 (2026-07-21), parking price back on the breakout shelf ahead of two binary FDA decisions: DTX401 (GSD Ia) PDUFA Aug 23 and UX111 (Sanfilippo A) PDUFA Sep 19. The July 30 Q2 print is a near-term event, but the paired PDUFAs are the trade — a coin-flip on support, not accelerating momentum.",
  "invalidation_trigger": "A weekly close below $28 breaks the June gene-therapy-reset breakout shelf and returns price toward the low-$20s post-setrusumab base; independently, a complete response letter or an action-date delay on either DTX401 (PDUFA 2026-08-23) or UX111 (PDUFA 2026-09-19) ends the thesis.",
  "catalyst_date": null,
  "outcome": "INVALIDATED",
  "outcome_date": "2026-07-22",
  "invalidation_fired": true,
  "themes": [
    "rare-disease-gene-therapy"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Cash $534M end Q1 2026 vs ~$185M quarterly net loss; ESOP share shelf filed — discounted equity raise risk if approvals slip. 2026 revenue guide $730-760M, profitability targeted 2027.",
    "Q2 2026 earnings est. late-July/early-Aug — confirm exact date; pipeline color is a soft catalyst ahead of the PDUFAs.",
    "Q2 2026 earnings confirmed 2026-07-30 — non-thesis binary ~3 trading days out; avoid fresh entries into the print, the real decisions are the PDUFAs.",
    "Paired FDA binaries are the trade: DTX401 (GSD Ia) 2026-08-23 (no AdCom anticipated), UX111 (Sanfilippo Type A) 2026-09-19 (prior CRL July 2025 on CMC).",
    "Momentum leg is spent: ran to ~$33.46 / RSI ~88 on 2026-07-03, round-tripped to $28.62 by 2026-07-21 — testing the ~$28 breakout shelf. This is now a binary-catalyst setup, not narrative momentum.",
    "GTX-102 Angelman Phase 3 Aspire topline H2 2026 — largest unpriced option, ~129 pts enrolled 2025-07.",
    "Cash $534M end Q1 2026 vs ~$185M quarterly net loss; share shelf on file = equity-raise risk if approvals slip. 2026 revenue guide $730-760M reaffirmed 2026-05-05, profitability targeted 2027.",
    "New pipeline: UX016 IND cleared (GNE myopathy sialic acid prodrug), Phase 1/2 H2 2026. Mean analyst target ~$57 (2026-07-13); RBC PT raised to $40 on 2026-07-07."
  ],
  "body_markdown": "## Current Thesis\nThe +50% June reset rally has matured and rolled over. After running to ~$33.46 on 2026-07-03 with RSI near 88, the stock has round-tripped to $28.62 (2026-07-21), parking price directly on the June gene-therapy-reset breakout shelf. What is left is a paired binary-catalyst name: a modest commercial base (Crysvita = $93M of $136M Q1 2026 revenue) carrying two FDA gene-therapy decisions — DTX401 (GSD Ia) PDUFA 2026-08-23 and UX111 (Sanfilippo Type A) PDUFA 2026-09-19 — plus an Angelman Phase 3 readout due H2 2026. The narrative-momentum leg that made this interesting in early July is spent; the next 8 weeks are pure event risk, front-loaded by a Q2 print on 2026-07-30. This is a coin-flip trade sitting on support, not an accelerating-narrative fat pitch.\n\n## Bull Case\n- Two FDA Priority Review decisions in view: DTX401 (pariglasgene brecaparvovec, GSD Ia AAV gene therapy) PDUFA 2026-08-23, and UX111 (rebisufligene etisparvovec, Sanfilippo Type A / MPS IIIA) PDUFA 2026-09-19. UX111 would be the first approved therapy for MPS IIIA, a disease with no pharmacological treatment anywhere.\n- Procedural tailwind on DTX401: the FDA informed the company an Advisory Committee meeting is not anticipated (disclosed with the BLA acceptance), removing a public-panel risk gate ahead of the 2026-08-23 date.\n- UX111 resubmission accepted 2026-04-02 with up to 8 years of follow-up versus natural-history decline; the prior CRL (July 2025) was CMC/manufacturing, not efficacy — the kind of issue a resubmission can resolve.\n- GTX-102 (apazunersen) Angelman Phase 3 Aspire fully enrolled 2025-07 (~129 patients, ages 4–17, full maternal UBE3A deletion), topline H2 2026, Breakthrough Therapy Designation — the largest embedded option and not priced into a $28 stock.\n- Commercial self-help intact: 2026 revenue guide reaffirmed at $730–760M on the Q1 call (2026-05-05), profitability targeted 2027, operating spend guided flat-to-down vs 2025. Pipeline widened 2026 with a UX016 IND clearance (sialic acid prodrug, GNE myopathy), Phase 1/2 starting H2 2026.\n- Sell-side skew remains wide: ~18-analyst Buy consensus with a mean target of ~$57 as of 2026-07-13 (range $25–$128); RBC Capital maintained Outperform and raised its target to $40 on 2026-07-07 — well above spot.\n\n## Bear Case\n- Setrusumab (UX143) is the standing warning: Phase 3 Orbit + Cosmic missed both primary annualized-fracture endpoints on 2025-12-29, hitting only secondary BMD. A promising mid-stage read here has already failed a Phase 3 once this cycle.\n- UX111 has already absorbed one CRL (July 2025). A second rejection on 2026-09-19 resets the narrative a third time, and CMC issues are not always cured by a single resubmission.\n- Both PDUFAs are genuine binaries with limited hedging window — approval optionality is priced, so a clean approval may sell the news while a CRL or delay gaps the stock lower.\n- Cash of $534M at end of Q1 2026 against a ~$185M quarterly net loss is finite; the ESOP/share shelf on file flags discounted-equity-raise risk if either approval slips runway.\n- Revenue concentration: Crysvita is ~68% of Q1 2026 revenue and faces eventual biosimilar/label competition — the base that funds the pipeline is itself exposed.\n- Price action already told the story: the June leg round-tripped ~14% off the high into the print without a broken headline, showing the momentum bid has left.\n\n## Setup & Price Structure\n- $28.62 on 2026-07-21, down from ~$33.46 on 2026-07-03. The reset-rally leg that drove RSI to ~88 has fully unwound; price now sits on the high-$20s breakout shelf rather than extending.\n- The June break was catalyzed by the paired PDUFA acceptances plus a conference spotlight, including a single-session +17.6% pop; none of that momentum structure survived into late July.\n- Levels: the low-$20s post-setrusumab floor is the downside base; the June breakout shelf sits at ~$28–30, which price is testing right now. A weekly hold above $28 keeps the reset structure alive into the FDA dates; a weekly close beneath it hands the tape back to the base.\n- Mean analyst target ~$57 sits roughly double spot, so the tape is discounting approval risk rather than pricing conviction — the asymmetry that favored early June buyers has narrowed as the event dates approach and the momentum premium bled out.\n- With Q2 results due 2026-07-30, the nearest move is a non-thesis earnings binary in front of the thesis-defining FDA binary on 2026-08-23. Fresh entries into that print carry gap risk on a report that does not resolve the actual trade.\n\n## Catalyst Calendar (next 30 days)\n\n- 2026-08-23 — DTX401 (GSD Ia) PDUFA action date. First hard binary; no Advisory Committee anticipated. First-in-disease approval if cleared.\n- 2026-09-19 — UX111 (Sanfilippo Type A) PDUFA action date (just outside the 30-day window but the second leg of the paired trade; prior CRL July 2025 on CMC).\n- H2 2026 (undated) — GTX-102 Angelman Phase 3 Aspire topline; the largest unpriced option.\n\n## Elapsed catalysts\n\n- 2026-07-30 — Q2 2026 financial results and corporate update (confirmed). Soft catalyst; pipeline color and cash-runway update ahead of the PDUFAs, plus reaffirmation risk on the $730–760M guide. *(passed 10d ago)*\n\n## What Would Change Our Mind\n- A weekly close below $28 breaks the June gene-therapy-reset breakout shelf and returns price toward the low-$20s post-setrusumab base — the structural signal that the reset thesis has failed before the catalysts arrive.\n- A complete response letter, label restriction, or action-date delay on DTX401 (2026-08-23) or UX111 (2026-09-19) ends the binary case regardless of price; a second UX111 CMC rejection is the highest-severity outcome.\n- A weak Q2 print on 2026-07-30 that cuts the $730–760M revenue guide or flags a near-term equity raise would confirm the runway bear case and pull the base lower ahead of the FDA dates.\n- On the upside, a clean weekly reclaim of the $30–33 zone on approval-anticipation flow with rising volume would re-establish the momentum leg and reopen the case toward the $40–57 target band.\n\n## Correlation Notes\n- Idiosyncratic binary risk dominates: the 2026-08-23 and 2026-09-19 PDUFAs are single-name FDA events, so realized volatility around those dates decouples from index beta. Position sizing should treat these as coin flips, not trend continuation.\n- Gene-therapy / rare-disease peer sentiment moves the tape between events. UniQure (QURE) rallied on 2026-06-17 alongside other clinical-stage names; watch Sarepta (SRPT), Rocket (RCKT), and Krystal (KRYS) approval/manufacturing headlines as read-throughs on AAV and CMC risk appetite.\n- Small-cap biotech beta (XBI) sets the backdrop; the June tape strength (\"small caps near record highs,\" 2026-06-17) inflated the reset rally and its fade tracks broader risk-off in the group.\n- Setrusumab is partnered with Mereo BioPharma (MREO) under strategic review post-miss; any UX143 program update is a shared datapoint between the two names.\n- Crysvita revenue concentration ties the commercial base to reimbursement and eventual biosimilar competition rather than to the gene-therapy narrative, a partial offset to pipeline binary risk.",
  "first_seen": "2026-07-01",
  "last_analyzed": "2026-07-25T07:43:29+00:00",
  "last_synthesized": "2026-07-25",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}